Kyorin Pharmaceutical Secures Exclusive License for Bayer's Novel OSA Treatment

MT NewswiresDec 16, 2024 19:28

Express News | Kyorin Pharmaceutical Co Ltd - Kyorin and Bayer Enter Into License Agreement for Novel Obstructive Sleep Apnea (Osa) Treatment:

BreakingsDec 16, 2024 10:34

Volume change rate ranking (10:00) - FISCO, Taiseioton, etc. ranked in.

In the volume change rate ranking, by comparing the average volume of the last 5 days with the volume on the day of distribution, it is possible to understand the trends of market participants' interests, etc. ■ Top volume change rates [As of December 9, 10:32] (Comparison with the average volume of the last 5 days) Stock Code Stock Name Volume 5-Day Average Volume Volume Change Rate Stock Price Change Rate <3807> Fisco 16968500 224898.825 8.43% 0.3709% <1904> Taisei

Fisco JapanDec 9, 2024 09:42

Kyorin Pharmaceutical: Confirmation letter

EDINETNov 13, 2024 14:27 · Announcements

Kyorin Pharmaceutical: Interim Report - 67th term (2024/04/01 - 2025/03/31)

EDINETNov 13, 2024 14:24 · Announcements

SASMED - 1Q sales slightly decreased, revenue from DTx platform business remains stable.

On the 8th, Sasmeldo <4263> announced its first quarter financial results for the June 2025 fiscal year (July-September 24). Operating income decreased by 1.4% year-on-year to 0.032 billion yen, operating loss was 0.161 billion yen (compared to a loss of 0.15 billion yen in the same period last year), ordinary loss was 0.163 billion yen (compared to a loss of 0.145 billion yen last year), and quarterly net loss was 0.163 billion yen (compared to a loss of 0.146 billion yen last year). There was no recognition of operating income for the DTx product business (same as the same period last year), and segment loss was 0.04 billion yen (compared to last year).

Fisco JapanNov 11, 2024 12:11